The increasing demand for cancer monoclonal antibodies is
mainly driven by the rising incidence of cancer, the growing
prevalence of risk factors like smoking, radiation exposure,
unhealthy lifestyles, and other contributing factors. Additionally,
the surge in research and development activities by market players
is expected to further fuel this demand throughout the forecast
period from 2024 to 2030.
LAS
VEGAS, Sept. 2, 2024 /PRNewswire/ --
DelveInsight's Cancer Monoclonal Antibodies Market
Insights report provides the current and forecast market
analysis, individual leading cancer monoclonal antibodies
companies' market shares, challenges, cancer monoclonal antibodies
market drivers, barriers, trends, and key market cancer monoclonal
antibodies companies in the market.
Key Takeaways from the Cancer Monoclonal Antibodies Market
Report
- As per DelveInsight estimates, North
America is anticipated to dominate the global cancer
monoclonal antibodies market during the forecast period.
- In the application segment of the cancer monoclonal antibodies
market, the breast cancer category had a significant revenue share
in the cancer monoclonal antibodies market in 2023.
- Notable cancer monoclonal antibodies companies such as GSK
plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG,
Johnson and Johnson Services Inc., Spectrum Pharmaceuticals Inc.,
Eurofins Scientific, Genmab AS, Bristol Myers Squibb Company,
Elli Lilly and Company, Amgen, Inc.,
AbbVie Inc., AstraZeneca Plc., CStone Pharmaceuticals, HiFiBiO
Therapeutics, and several others, are currently operating in
the cancer monoclonal antibodies market.
- In April 2024, CE approved
the VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* to
identify metastatic breast cancer patients with low HER2 expression
for whom ENHERTU® (trastuzumab deruxtecan) may be considered as a
targeted treatment.
- In December 2023, CStone
Pharmaceuticals announced that the National Medical Products
Administration (NMPA) of China
approved the supplemental biologics license application (sBLA) for
sugemalimab (Cejemly®) in combination with fluorouracil and
platinum-based chemotherapy as first-line treatment of unresectable
locally advanced, recurrent, or metastatic esophageal squamous cell
carcinoma (ESCC). Sugemalimab became the world's first anti-PD-L1
monoclonal antibody approved for the first-line ESCC
indication.
To read more about the latest highlights related to the cancer
monoclonal antibodies market, get a snapshot of the key highlights
entailed in the Global Cancer Monoclonal Antibodies Market
Report
Cancer Monoclonal Antibodies Overview
Monoclonal antibodies (mAbs) have revolutionized cancer
treatment by offering highly targeted therapies that specifically
attack cancer cells while sparing healthy tissue. These antibodies
are laboratory-made molecules designed to bind to specific antigens
on the surface of cancer cells. By recognizing these unique
markers, monoclonal antibodies can interfere with the growth and
spread of cancer in several ways. For example, they can block
signals that stimulate cancer cell proliferation, mark cancer cells
for destruction by the immune system, or deliver toxic substances
directly to the cancer cells. This specificity reduces the side
effects typically associated with conventional chemotherapy and
radiation, making mAbs an essential component of modern
oncology.
There are several types of monoclonal antibodies used in cancer
treatment, including naked mAbs, which work by themselves, and
conjugated mAbs, which are linked to drugs or radioactive
particles. Some well-known examples include Rituximab, used in the
treatment of certain types of lymphoma, and Trastuzumab, which
targets HER2-positive breast cancer. These therapies have shown
significant success in improving survival rates and quality of life
for many patients. However, challenges remain, such as the
development of resistance by cancer cells and the high cost of
production. Ongoing research aims to overcome these hurdles by
developing more effective and affordable mAbs, as well as combining
them with other treatments to enhance their efficacy.
Cancer Monoclonal Antibodies Market Insights
North America held the largest
share of the cancer monoclonal antibodies market in 2023, driven by
several factors. The region's leading position is attributed to the
rising incidence of cancers, greater exposure to carcinogens such
as smoking, radiation, and viruses, and recent regulatory approvals
that favor the growth of the cancer monoclonal antibodies market in
North America.
Furthermore, the increasing number of regulatory approvals for
these antibodies is expected to further stimulate market growth.
For instance, in October 2022, the
FDA approved the combination of durvalumab (IMFINZI), a human
monoclonal antibody, with the experimental drug tremelimumab for
treating unresectable hepatocellular carcinoma.
The large patient population in North
America is likely to drive demand for cancer monoclonal
antibodies, leading to market expansion in the coming years.
Therefore, the combined influence of these factors is expected to
contribute significantly to the growth of the cancer monoclonal
antibodies Market in North America
from 2024 to 2030.
To know more about why North
America is leading the market growth in the cancer
monoclonal antibodies market, get a snapshot of the Cancer
Monoclonal Antibodies Market Outlook
Cancer Monoclonal Antibodies Market Dynamics
The global market for cancer monoclonal antibodies has
experienced significant growth over the past decade, driven by the
increasing incidence of cancer, advancements in
biotechnology, and the rising demand for targeted
therapies. Monoclonal antibodies, which are designed to
specifically target cancer cells while sparing healthy tissue, have
become a cornerstone in the treatment of various cancers. Their
specificity and reduced side effects compared to traditional
chemotherapy have made them an attractive option for both patients
and healthcare providers.
One of the key dynamics shaping the cancer monoclonal antibodies
market is the ongoing innovation in antibody engineering.
Techniques such as antibody-drug conjugates, bispecific
antibodies, and immune checkpoint inhibitors have expanded the
therapeutic potential of mAbs, leading to the development of more
effective and versatile cancer treatments. These innovations have
not only enhanced the efficacy of existing therapies but have also
opened up new avenues for addressing previously untreatable or
resistant forms of cancer.
The competitive landscape of the market is also influenced by
the expiration of patents on several blockbuster mAbs, paving the
way for biosimilars to enter the market. Biosimilars, which are
essentially generic versions of biologic drugs, offer
similar efficacy at a lower cost, making cancer treatment more
accessible. However, the introduction of biosimilars has
also intensified competition among pharmaceutical companies,
driving the need for continuous innovation and the development of
next-generation therapies to maintain market share.
Regulatory and reimbursement challenges also play a crucial role
in the market dynamics. The stringent regulatory
requirements for the approval of mAbs, coupled with the high
costs associated with their development and manufacturing, can pose
barriers to market entry. Additionally, securing favorable
reimbursement from healthcare systems is critical for the
widespread adoption of these therapies. As healthcare budgets
become increasingly strained, especially in the wake of the
COVID-19 pandemic, the cost-effectiveness of mAbs will likely be a
focal point in discussions between pharmaceutical companies,
regulators, and payers.
In conclusion, the cancer monoclonal antibodies market is poised
for continued growth, driven by technological advancements, the
entry of biosimilars, and the rising demand for personalized cancer
therapies. However, the market will need to navigate challenges
related to regulation, competition, and cost-effectiveness to
sustain its momentum. As research and development in the field of
immuno-oncology continue to advance, the landscape of cancer
treatment is likely to evolve, offering new hope for patients and
further solidifying the role of monoclonal antibodies in cancer
care.
Get a sneak peek at the cancer monoclonal antibodies market
dynamics @ Cancer Monoclonal Antibodies Market Dynamics
Analysis
Report
Metrics
|
Details
|
Coverage
|
Global
|
Study Period
|
2021–2030
|
Cancer Monoclonal
Antibodies Market CAGR
|
~10%
|
Cancer Monoclonal
Antibodies Market Size by 2030
|
~USD 157
Billion
|
Key Cancer Monoclonal
Antibodies Companies
|
GSK plc, F. Hoffmann-La
Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson and Johnson
Services Inc., Spectrum Pharmaceuticals Inc., Eurofins Scientific,
Genmab AS, Bristol Myers Squibb Company, Elli Lilly and Company,
Amgen, Inc., AbbVie Inc., AstraZeneca Plc., CStone Pharmaceuticals,
HiFiBiO Therapeutics, among others
|
Cancer Monoclonal Antibodies Market Assessment
- Cancer Monoclonal Antibodies Market Segmentation
-
- Cancer Monoclonal Antibodies Market Segmentation By
Type: Humanized Antibodies, Chimeric Antibodies, Murine
Antibodies
- Cancer Monoclonal Antibodies Market Segmentation By
Application: Blood Cancer, Breast Cancer, Liver Cancer,
Colorectal Cancer, and Others
- Cancer Monoclonal Antibodies Market Segmentation By End
Users: Hospitals, Research Institutions & Laboratories, and
Others
- Cancer Monoclonal Antibodies Market Segmentation By
Geography: North America,
Europe, Asia-Pacific, and Rest of World
- Porter's Five Forces Analysis, Product Profiles, Case
Studies, KOL's Views, Analyst's View
Which MedTech key players in the cancer monoclonal antibodies
market are set to emerge as the trendsetter explore @ Cancer
Monoclonal Antibodies Companies
Table of Contents
1
|
Cancer Monoclonal
Antibodies Market Report Introduction
|
2
|
Cancer Monoclonal
Antibodies Market Executive Summary
|
3
|
Competitive
Landscape
|
4
|
Regulatory
Analysis
|
5
|
Cancer Monoclonal
Antibodies Market Key Factors Analysis
|
6
|
Cancer Monoclonal
Antibodies Market Porter's Five Forces Analysis
|
7
|
Cancer Monoclonal
Antibodies Market Layout
|
8
|
Cancer Monoclonal
Antibodies Market Company and Product Profiles
|
9
|
KOL Views
|
10
|
Project
Approach
|
11
|
About
DelveInsight
|
12
|
Disclaimer &
Contact Us
|
Interested in knowing the cancer monoclonal antibodies market by
2030? Click to get a snapshot of the Cancer Monoclonal
Antibodies Market Trends
Related Reports
Monoclonal Antibodies Competitive Landscape
Monoclonal Antibodies Competitive Landscape –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key monoclonal antibodies
companies, including Novartis, Novartis, Gmax Biopharm, Omeros
Corporation, Merck Sharp & Dohme, Disc Medicine, Eledon
Pharmaceuticals, Alexion AstraZeneca Rare Disease, Chinook
Therapeutics, Omeros Corporation, Novo Nordisk, Merck KGaA,
Bristol-Myers Squibb, Jacobio Pharmaceuticals, Nectin Therapeutics
Ltd, Y-mAbs Therapeutics, OncoResponse, Inc., Fate
Therapeutics, Pelican Therapeutics, Inc., Heat Biologics, Oncternal
Therapeutics, Phanes Therapeutics, Pharmacyclics LLC, Immunitas
Therapeutics, Hummingbird Bioscience, Inc., Sanofi, Takeda, Agenus
Inc., Aulos Bioscience, Inc., ChemomAb Ltd, Celldex Therapeutics,
Celgene, Janssen Research & Development, LLC, Adaptive
Biotechnologies, BeiGene, Vaccinex Inc., Jasper Therapeutics, Inc.,
Shanghai Junshi Bioscience Co., Ltd., TopAlliance Biosciences,
Inc., among others.
Cancer Therapy Market
Cancer Therapy Market Insight, Competitive Landscape, and
Market Forecast – 2030 report delivers an in-depth
understanding of market trends, market drivers, market barriers,
and key cancer therapy companies, including GlaxoSmithKline, Eli
Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen
Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc,
AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen
Global Services, LLC, Elekta AB, Varian Medical Systems, Inc.,
Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA,
Panacea Medical Technologies Pvt. Ltd., among others.
Oncology Drugs Market
Oncology Drugs Market Insight, Competitive Landscape, and
Market Forecast – 2030 report delivers an in-depth
understanding of market trends, market drivers, market barriers,
and key oncology drugs companies, including GlaxoSmithKline, Eli
Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen
Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc,
AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen
Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos
Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz
International GmbH, BeiGene, among others.
Non-small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, Epidemiology, and
Market Forecast – 2032 report deliver an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key NSCLC companies, including EMD Serono, Merck,
Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies,
Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward
Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb,
Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen,
Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic
Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo,
Inc., AstraZeneca, Precision Biologics, Inc, Promontory
Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals,
Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance
Biotherapeutics, Inc., Innate Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/global-cancer-monoclonal-antibodies-market-to-cross-usd-157-billion-mark-by-2030--delveinsight-302235692.html
SOURCE DelveInsight Business Research, LLP